Topical azelaic acid therapy for palpebral lesions of melanoma in situ (lentigo maligna) and for melanoma in situ progressed to invasive melanoma. A report on four cases

M. Nazzaro-Porro, G. Zina, A. S. Breathnach, M. Bernengo, S. Passi, M. Picardo, L. Balus, C. De Luca

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Azelaic acid has been shown to have a biological antiproliferative and cytotoxic effect on the abnormally hyperactive and malignant melanocyte both in vivo and in vitro. Here, beneficial effects of topical azelaic therapy on four facial lesions where surgery was not considered to be a primary or available option are described. Two were cases of melanoma in situ involving the lower eyelid. In one, complete regression of the lesion was achieved and maintained for six years. In the other, the overall lesional area was greatly reduced, allowing discrete excision of small relapses with no recurrences for up to nine years: this case demonstrates an adjuvant effect of azelaic acid therapy on surgery, in reducing the overall area to be excised. The other two cases were of melanoma in situ progressed to invasive malignant melanoma in which complete clinical regression of the lesions was achieved, in one case for up to five years. Treatment in these cases was essentially palliative, with probable prolongation of life in one, and certainly, improvement in quality of remaining life in both. Newer formulations for topical application, possibly combined with oral or even systemic administration, could lead to increased delivery of azelaic acid to lesional sites and reduction in treatment time with similar cases in future.

Original languageEnglish
Pages (from-to)79-85
Number of pages7
JournalGiornale Italiano di Dermatologia e Venereologia
Volume133
Issue number2
Publication statusPublished - 1998

Fingerprint

Hutchinson's Melanotic Freckle
Eyelids
Melanoma
Life Support Care
Recurrence
Melanocytes
Therapeutics
Quality of Life
azelaic acid

Keywords

  • Dicarboxylic acids
  • Hutchinson's melanotic freckle
  • Melanoma drug therapy
  • Skin neoplasms

ASJC Scopus subject areas

  • Dermatology

Cite this

Topical azelaic acid therapy for palpebral lesions of melanoma in situ (lentigo maligna) and for melanoma in situ progressed to invasive melanoma. A report on four cases. / Nazzaro-Porro, M.; Zina, G.; Breathnach, A. S.; Bernengo, M.; Passi, S.; Picardo, M.; Balus, L.; De Luca, C.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 133, No. 2, 1998, p. 79-85.

Research output: Contribution to journalArticle

@article{4e6e3ac41fd14dae9e824265279614be,
title = "Topical azelaic acid therapy for palpebral lesions of melanoma in situ (lentigo maligna) and for melanoma in situ progressed to invasive melanoma. A report on four cases",
abstract = "Azelaic acid has been shown to have a biological antiproliferative and cytotoxic effect on the abnormally hyperactive and malignant melanocyte both in vivo and in vitro. Here, beneficial effects of topical azelaic therapy on four facial lesions where surgery was not considered to be a primary or available option are described. Two were cases of melanoma in situ involving the lower eyelid. In one, complete regression of the lesion was achieved and maintained for six years. In the other, the overall lesional area was greatly reduced, allowing discrete excision of small relapses with no recurrences for up to nine years: this case demonstrates an adjuvant effect of azelaic acid therapy on surgery, in reducing the overall area to be excised. The other two cases were of melanoma in situ progressed to invasive malignant melanoma in which complete clinical regression of the lesions was achieved, in one case for up to five years. Treatment in these cases was essentially palliative, with probable prolongation of life in one, and certainly, improvement in quality of remaining life in both. Newer formulations for topical application, possibly combined with oral or even systemic administration, could lead to increased delivery of azelaic acid to lesional sites and reduction in treatment time with similar cases in future.",
keywords = "Dicarboxylic acids, Hutchinson's melanotic freckle, Melanoma drug therapy, Skin neoplasms",
author = "M. Nazzaro-Porro and G. Zina and Breathnach, {A. S.} and M. Bernengo and S. Passi and M. Picardo and L. Balus and {De Luca}, C.",
year = "1998",
language = "English",
volume = "133",
pages = "79--85",
journal = "Minerva dermatologica",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Topical azelaic acid therapy for palpebral lesions of melanoma in situ (lentigo maligna) and for melanoma in situ progressed to invasive melanoma. A report on four cases

AU - Nazzaro-Porro, M.

AU - Zina, G.

AU - Breathnach, A. S.

AU - Bernengo, M.

AU - Passi, S.

AU - Picardo, M.

AU - Balus, L.

AU - De Luca, C.

PY - 1998

Y1 - 1998

N2 - Azelaic acid has been shown to have a biological antiproliferative and cytotoxic effect on the abnormally hyperactive and malignant melanocyte both in vivo and in vitro. Here, beneficial effects of topical azelaic therapy on four facial lesions where surgery was not considered to be a primary or available option are described. Two were cases of melanoma in situ involving the lower eyelid. In one, complete regression of the lesion was achieved and maintained for six years. In the other, the overall lesional area was greatly reduced, allowing discrete excision of small relapses with no recurrences for up to nine years: this case demonstrates an adjuvant effect of azelaic acid therapy on surgery, in reducing the overall area to be excised. The other two cases were of melanoma in situ progressed to invasive malignant melanoma in which complete clinical regression of the lesions was achieved, in one case for up to five years. Treatment in these cases was essentially palliative, with probable prolongation of life in one, and certainly, improvement in quality of remaining life in both. Newer formulations for topical application, possibly combined with oral or even systemic administration, could lead to increased delivery of azelaic acid to lesional sites and reduction in treatment time with similar cases in future.

AB - Azelaic acid has been shown to have a biological antiproliferative and cytotoxic effect on the abnormally hyperactive and malignant melanocyte both in vivo and in vitro. Here, beneficial effects of topical azelaic therapy on four facial lesions where surgery was not considered to be a primary or available option are described. Two were cases of melanoma in situ involving the lower eyelid. In one, complete regression of the lesion was achieved and maintained for six years. In the other, the overall lesional area was greatly reduced, allowing discrete excision of small relapses with no recurrences for up to nine years: this case demonstrates an adjuvant effect of azelaic acid therapy on surgery, in reducing the overall area to be excised. The other two cases were of melanoma in situ progressed to invasive malignant melanoma in which complete clinical regression of the lesions was achieved, in one case for up to five years. Treatment in these cases was essentially palliative, with probable prolongation of life in one, and certainly, improvement in quality of remaining life in both. Newer formulations for topical application, possibly combined with oral or even systemic administration, could lead to increased delivery of azelaic acid to lesional sites and reduction in treatment time with similar cases in future.

KW - Dicarboxylic acids

KW - Hutchinson's melanotic freckle

KW - Melanoma drug therapy

KW - Skin neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0031814959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031814959&partnerID=8YFLogxK

M3 - Article

VL - 133

SP - 79

EP - 85

JO - Minerva dermatologica

JF - Minerva dermatologica

SN - 0392-0488

IS - 2

ER -